In the past decade, it has become clear that the immune system can be manipulated to induce cancer regression, durable disease stabilization, and long-term survival in a substantial fraction of cancer patients. Building on this success, members of the Immunology and Cancer (IC) Program aim to better understand the interface between the host immune system and a malignant tumor, and to use this knowledge to develop more effective immunotherapies for the treatment of a broad array of cancer types. The central themes of the Program include: 1) basic immunology relevant to the cancer context (including innate immunity, lymphocyte activation, and peripheral inflammation/tolerance regulation); 2) preclinical mouse models of anti-tumor immunity; and 3) human cancer immunology and immunotherapy. Through the pursuit of these themes, IC members have made fundamental discoveries regarding immune regulation and anti-tumor immunity, and in collaboration with clinical colleagues in the Clinical and Experimental Therapeutics (CET) Program, have leveraged many of these concepts for the development of novel immunotherapies that are now being evaluated in the clinic. The Program is co-led by Thomas Gajewski, MD PhD, Professor of Pathology and Medicine, and Peter Savage, PhD, Associate Professor of Pathology. Dr. Gajewski is a physician-scientist and international leader in the field of tumor immunology and the successful implementation of cancer immunotherapy in human patients. Dr. Savage is a recognized leader in the study of regulatory T cell biology and the role of these cells in the regulation of anti-tumor immunity. There are 18 program members from seven Departments. The IC Program has recruited five new faculty since 2013, including Jason Luke, MD, Melody Swartz, PhD, Jun Huang, PhD, Seungmin Hwang, PhD, and James Labelle, MD, PhD. During the last funding period (2013-2016), program members have published 224 cancer-related articles (with 13% intraprogrammatic and 19% interprogrammatic publications). As of January 2017, Program members hold 36 grants, and are supported by $6.6M (direct costs) in NIH extramural funding, including 6 grants and $1.0M (direct costs) from the NCI. Program members are supported by an additional $2.23 M (direct costs) in non- peer-reviewed support, resulting in total support of $8.9 M (direct costs).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584

Showing the most recent 10 out of 668 publications